ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
AstraZeneca
Centre Paul Strauss
Artios Pharma Ltd
Novartis
Abramson Cancer Center at Penn Medicine
Hospices Civils de Lyon
Pfizer
Pfizer
Hummingbird Bioscience
Hellenic Cooperative Oncology Group
Incyte Corporation
MedSIR
MedSIR
MedSIR
Massachusetts General Hospital
Esperas Pharma Inc.
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Queen Mary University of London
Cedars-Sinai Medical Center
National Cancer Institute (NCI)
Georgetown University
Daiichi Sankyo
Acepodia Biotech, Inc.
Astellas Pharma Inc
Astellas Pharma Inc
Vincerx Pharma, Inc.
Pfizer
The Netherlands Cancer Institute
Mundipharma Research Limited
Instituto Nacional de Cancer, Brazil
Radiation Therapy Oncology Group
NantCell, Inc.
G1 Therapeutics, Inc.
Ain Shams University
Dartmouth-Hitchcock Medical Center
Cedars-Sinai Medical Center
UNC Lineberger Comprehensive Cancer Center
Eli Lilly and Company
NextCure, Inc.
ETOP IBCSG Partners Foundation
ETOP IBCSG Partners Foundation
Capital Medical University
Indiana University
UNICANCER
UNC Lineberger Comprehensive Cancer Center
Eli Lilly and Company
Instituto Nacional de Cancer, Brazil